Meu SciELO
Serviços Personalizados
Journal
Artigo
Indicadores
Citado por SciELO
Acessos
Links relacionados
Citado por Google
Similares em SciELO
Similares em Google
Compartilhar
Archivos de Prevención de Riesgos Laborales
versão On-line ISSN 1578-2549
Resumo
INGLES-TORRUELLA, Joan et al. Reactogenicity study of mRNA vaccines against COVID-19. Arch Prev Riesgos Labor [online]. 2023, vol.26, n.2, pp.106-126. Epub 24-Jul-2023. ISSN 1578-2549. https://dx.doi.org/10.12961/aprl.2022.26.02.02.
Objective:
To compare the reactogenicity between the types of mRNA Commirnaty® (Pfizer) and Spikevax® (Moderna) vaccines against COVID-19 in a healthcare population.
Methods:
Cross sectional study of short-term adverse effects and their consequences (sick leave, limitations of daily life, etc.) after the administration of the first and second doses of both vaccines in professionals and students of a health institution. A questionnaire on symptoms and their consequences was administered seven days after each vaccination dose. The prevalence and 95% confidence interval (95%CI) were calculated. Differences between vaccines were quantified using the odds ratio (OR) and its 95%CI.
Results:
The questionnaire was completed by 1924 and 1170 healthcare providers (response rates 62.2% and 39.1%) after the first and second doses, respectively, of the Commirnaty® vaccine, and 410 (56.0%) and 107 (15.0%) of Spikevax®. After the first dose of Comirnaty®, 67.4% presented some adverse effect, and 76.1% for Spikevax® (OR 1.5 95%CI 1.2-1.9). In general, women and young people showed greater reactogenicity and differences between vaccines. Consequences of adverse effects were more frequent for Spikevax®. The reactogenicity was higher after the second than the first dose, for both vaccines (Comirnaty®: 67.4% vs. 75.6%; Spikevax®: 76.1% vs. 87.9%.
Conclusions:
The greater reactogenicity and its consequences, for the first and second dose of the Spikevax® vaccine compared to Comirnaty®, and of the second dose compared to the first dose of both vaccines, provides useful knowledge for planning vaccination against COVID-19 campaigns in healthcare settings.
Palavras-chave : SARS-CoV-2; COVID-19-vaccination; mRNA vaccines; adverse reactions; health care workers.